Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.
Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.
Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302
A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.
Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.
Believers in Peregrine's lung cancer drug bavituximab state their case.
Nate Sadeghi examines Peregrine's lung cancer drug bavituximab
Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.
There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.